A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

Clinical trial NCT03963232 · COMPLETED

Trial details

NCT number: NCT03963232
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Episodic Migraine

Start date: 2019-07-30
Primary completion: 2021-07-27
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.